Ocular Parasitosis Caused by Protozoan Infection during Travel: Focus on Prevention and Treatment

Abstract

International travel is rising quickly worldwide. Many people travel to tropical and subtropical areas, where there has been increasing exposure of travelers to infectious pathogens. Ocular parasitic infections are more prevalent in these geographical areas and they can lead to morbidity and mortality, often due to late or misdiagnosis due to the unfamiliarity of health staff with these diseases. This is an up-to-date comprehensive review article that familiarizes physicians with ocular signs and symptoms, treatment, prevention, and geographic distribution of some parasites associated with travel.

Keywords: *Acanthamoeba*, American trypanosomiasis, eye, giardiasis, leishmaniasis, malaria, parasitosis, protozoan infection, toxoplasmosis, travel

Introduction

International travel is rising quickly worldwide.[1] In 2015, the number of travelers exceeded 1.2 billion and it is estimated that it may reach 1.6 billion in 2020 in all countries.[2-4] Many of them travel to tropical and subtropical areas and participate in outdoor activities.[5] Travel to such places and these behavioral habits cause increasing exposure to infectious pathogens and travelers can easily acquire and transmit these diseases.[5,6] Ocular infections caused by various parasites in humans are more prevalent in tropical and subtropical geographical areas. These infections can lead to ocular morbidity and mortality largely because of misdiagnosis, often from unfamiliarity of healthcare workers with the disease course.

For identification of the causes of ocular infection, matching general and ocular symptoms and signs with travel history to endemic areas, dietary history, and advances in diagnosis are important.[7] This article familiarizes ophthalmologists and general physicians with some ocular parasites. For each disease, we describe the causative agent, geographic distribution, clinical ocular presentation, diagnostic methods, treatment, and prevention in travelers.

Methods

A literature search was performed using PubMed Medline until 2016. To collect material for this study, a detailed search of the PubMed database was performed using any term related to ophthalmology. The terms were as follows: “eye,” “vision,” “visual,” “optic,” “lens,” “retina,” “uvea,” “choroid,” “cilia,” “cornea,” “sclera” AND Giardiasis, Leishmaniasis, Malaria, *Acanthamoeba*, American trypanosomiasis, Toxoplasmosis, AND travel.

Based on this research, the total number of articles accounting for giardiasis was 47, 380 for leishmaniasis, 1362 for malaria, 3988 for *Acanthamoeba*, 232 for American trypanosomiasis, and 4801 for toxoplasmosis. Articles published other than English language, lacking full-length forms, and those published before 1990 (totally 5507 papers) were excluded from this review. Studies in English language emphasizing on ocular manifestation of these infections and their associations with travel were subjected (2763). All searches were combined, and we removed duplicate manuscripts and irrelevant articles by reading their titles and abstracts (122 of 2763). The electronic search was classified using the following phrases: travel, ocular infection, ocular parasitic presentation, diagnosis, treatment, and prevention.

How to cite this article: Izadi M, Pourazizi M, Babaei M, Saffaei A, Alemzadeh-Ansari MH. Ocular parasitosis caused by protozoan infection during travel: Focus on prevention and treatment. Int J Prev Med 2018:9:79.

Morteza Izadi, Mohsen Pourazizi1, Mahmoud Babaei2, Ali Saffaei3, Mohammad-Hasan Alemzadeh-Ansari1

Health Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran, 1Department of Ophthalmology, Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran, 2Department of Ophthalmology, Baqiyatallah University of Medical Sciences, Tehran, Iran, 3Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran and Student Research Committee, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Address for correspondence:
Dr. Mohammad-Hasan Alemzadeh-Ansari
Department of Ophthalmology, Isfahan Eye Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
E-mail: mh.aansari@gmail.com

Access this article online

Website: www.ipvmjournal.net/www.ipvm.ir
DOI: 10.4103/ipvm.IPVM_161_18
Quick Response Code:
Results

The most important ocular diseases caused by protozoans include giardiasis, leishmaniasis, malaria, *Acanthamoeba*, American trypanosomiasis, and toxoplasmosis. Treatment and prevention recommendation are summarized in Table 1.

**Giardiasis**

Giardiasis is caused by an enteric flagellated protozoan parasite of the genus *Giardia*. *Giardia* is transmitted through ingestion of cysts in contaminated food or water, or directly through the fecal/oral route.[8]

In one study, the risk of travel-associated giardiasis was estimated at 5.3 per 100,000 travelers with highest incidences in travelers from the Indian Subcontinent, East and West Africa, South and South East Asia, and South and Central America.[9‑11] In addition, the highest risk was seen in the youngest age group, with a decreasing risk with higher age.[11] Caucasian ethnicity, long travel time (more than 32 days), traveling to South or South East Asia, afebrile presentation, and presenting with gastrointestinal symptoms were all associated with giardiasis in returned tropical travelers.[12] The peak incidence of giardiasis was shown in travelers returning from South Asia, the Middle East and South America.[13]

| Disease/infection | Causative agent | Prevention | Treatment agent | Dosage |
|-------------------|----------------|------------|-----------------|--------|
| Giardiasis | *Giardia lamblia* | Avoidance of contaminated water and foods. Avoidance of recreational water activities and swimming | Tinidazole | 2 g orally, single dose |
| | | | Nitazoxanide | 500 mg orally two times per day for 3 days |
| | | | Metronidazole | 500 mg orally twice daily or 250 mg orally three times per day; duration 5-7 days |
| | | | Albendazole | 400 mg orally once daily for 5 days |
| | | | Mebendazole | 200 mg orally three times per day for 5 days |
| | | | Paromomycin | 10 mg/kg orally three times per day for 5-10 days |
| | | | Furazolidone | 100 mg orally four times per day for 7-10 days |
| | | | Quinacrine | 100 mg orally three times per day for 5 days |
| Leishmaniasis | *Leishmania* spp. | Protection against sandfly bites, limitation of outdoor activities, wearing protective clothing, use of fans or ventilators, use of bed nets, use of wide-mesh nets with a pyrethroid-containing insecticide, and applying N, N-diethyl-meta-toluamide-containing repellents to uncovered skin | Fluconazole | 200 mg orally once daily for 6 weeks |
| | | | Ketoconazole | 600 mg orally once daily for 28 days |
| | | | Miltefosine | 2.5 mg/kg (maximum 150 mg) orally in three divided doses for 28 days; if weight is 30-44 kg, use 50 mg orally twice daily |
| | | | Sodium stibogluconate | 20 mg Sb/kg/day intravenously or intramuscularly for 10-20 days |
| | | | Meglumine antimoniate | 20 mg Sb/kg/day intravenously or intramuscularly for 10-20 days |
| | | | Amphotericin B deoxycholate | 0.5-1 mg/kg intravenously dosed daily or every other day for a cumulative total dose of 15-30 mg/kg |
| | | | Liposomal amphotericin B (Ambisome) | 3 mg/kg intravenously daily for five to seven doses, such as days 1-5, 10 |
| | | | Pentamidine isethionate | 3-4 mg/kg intravenously or intramuscularly every other day for four to seven doses or until healed |

*Contd...*
| Disease/infection | Causative agent | Prevention | Treatment agent | Dosage |
|-------------------|----------------|------------|----------------|--------|
| Malaria           | *Plasmodium falciparum* | Most travelers develop malarial disease because they were not aware of personal protection measures and/or chemoprophylactic regimens. All travelers to endemic areas for malaria should be educated about personal and environmental measures on protection against *Anopheles* mosquito bites. These measures included wearing clothing that covers as much skin as possible (long sleeves, long pants, and fully closed shoes with socks), using a repellent containing N, N-diethyl-3-meta-toluamide or picaridin, treating clothing with a pyrethroid in the regions with high risk for malaria, and sleeping under a permethrin-treated bed net in not well-screened or air-conditioned locations | Chloroquine | 600 mg base (=1000 mg salt) orally immediately, followed by 300 mg base (=500 mg salt) orally at 6, 24, and 48 h; total dose: 1500 mg base (=2500 mg salt) |
|                   |                 |            | Hydroxychloroquine | 620 mg base (=800 mg salt) orally immediately, followed by 310 mg base (=400 mg salt) orally at 6, 24, and 48 h; total dose: 1550 mg base (=2000 mg salt) |
|                   |                 |            | Atovaquone-proguanil | 4 adult tabs orally once daily for 3 days |
|                   |                 |            | Quinine plus one of the following: doxycycline, tetracycline, or clindamycin | Quinine: 542 mg base (=650 mg salt) orally three times daily for 3 or 7 days plus one of the following - doxycycline: 100 mg orally twice daily for 7 days, tetracycline: 250 mg orally four times daily for 7 days, clindamycin: 20 mg base/kg/day (up to 1.8 g) orally divided three times daily for 7 days |
|                   |                 |            | Mefloquine | 684 mg base (=750 mg salt) orally as initial dose, followed by 456 mg base (=500 mg salt) orally given 6-12 h after initial dose; total dose=1250 mg salt |
|                   |                 |            | Artemisinin | Doses must be adjusted based on the available combination formulation and body weight |
|                   |                 |            | Chlorhexidine combined with Brolene | Every hour until 2-3 days around the clock, then every hour while awake until 3 days, then tapered to 4 times a day |
|                   |                 |            | Other treatments such as propamidine, miconazole, and neomycin also has been successful in only a few instances | |
| Acanthamoeba keratitis | *Acanthamoeba* spp. | Wear, replace, and clean contact lenses and their cases according to the eye care provider and the manufacturer’s guidelines. Remove contact lenses before carrying out any activity involving contact with water bodies such as swimming, showering, or using a hot tub. Avoid eye contamination or corneal trauma using adequate eye protection | Chlorhexidine | Every hour until 2-3 days around the clock, then every hour while awake until 3 days, then tapered to 4 times a day |
| Chagas’ disease   | *Trypanosoma cruzi* | Vector control by indoor residual insecticide spraying and improvement of housing to prevent bugs becoming established in cracked walls and thatched roofing. Sugar cane presses and other food preparation facilities should be protected from possible contamination by infected reduvid bugs sleep under a mosquito net and treat bedding with an insecticide to prevent bites | Benznidazole | 5-7 mg/kg per day orally in two divided doses for 60 days |
|                   |                 |            | Nifurtimox | 8-10 mg/kg per day orally in three or four divided doses for 90-120 days |

Contd...
Table 1: Contd...

| Disease/infection | Causative agent | Prevention | Treatment agent | Dosage |
|-------------------|----------------|------------|----------------|--------|
| Toxoplasmosis     | *Toxoplasma gondii* | Pregnant women should not eat undercooked meat to avoid vertical transmission. Steak tartare should be avoided. Barbecued meats should be well grilled or avoided | Pyrimethamine | Oral: 50-75 mg/day for 1-3 weeks depending on patient’s tolerance and response, then may reduce dose by 50% and continue for 4-5 weeks; use with a sulfonamide in combination with leucovorin calcium |

Extraintestinal manifestations of giardiasis are rarely reported, but in a recent study around 33% of patients affected by giardiasis showed long-term extraintestinal symptoms; hence, these symptoms are not as rare as previously assumed. Ocular complications included iridocyclitis, choroiditis, retinal hemorrhages, salt and pepper degeneration, and severe bilateral anterior uveitis. Susceptibility to ocular complications with giardiasis seems higher in smaller children. It has been proposed that salt and pepper degeneration may be a consequence of toxic metabolites produced by the parasites, not direct invasion. Several different treatments for giardiasis have been described; first-line therapy for giardiasis is generally tinidazole and metronidazole. Metronidazole 500 mg orally twice daily or 250 mg orally three times per day is recommended, for a duration of 5–7 days. Also, it is recommended that for children it should be orally divided three times per day for 5–7 days (maximum 250 mg per dose). Another choice for giardiasis treatment approved by the Food and Drug Administration is nitazoxanide. Third-line therapies for pregnant or refractory cases are paromomycin and quinacrine, respectively.

**Prevention and recommendation: Giardiasis**

Since the main route of transmission of giardiasis is ingestion of contaminated water and foods, our recommendations to travelers for prevention are consumption of only treated water and cooked foods, especially when traveling to locations with high incidences of the parasite. In addition, recreational water activities and swimming should be performed with caution in suspected water in these locations. Suitable treatment for giardiasis is important for reducing ocular complications.

**Leishmaniasis**

Leishmaniasis is a tropical parasitic disease caused by obligate intramacrophage protozoans. These parasites are transmitted to humans during blood sucking by female sand flies. Travelers to endemic areas are at risk. Ocular findings in cutaneous leishmaniasis indicate a local phenomenon due to the initial site of the bite near the eyelids. Ptosis, cicatricial ectropion or entropion, bilateral lagophthalmia, and chronic ulcerative blepharoconjunctivitis have been described. Extension of the infection to lacrimal ducts may cause dacryocystitis. Ocular manifestations in visceral leishmaniasis, also known as kala-azar, are predominantly retinal vascular abnormalities, including focal retinal whitening, cotton wool spots, and hemorrhages with increased vessel tortuosity. Bilateral, multifocal retinal hemorrhages can be improved by specific antileishmanial therapy. Treatment is also summarized in Table 1.

**Prevention and recommendation: Leishmaniasis**

There is still no available vaccine against leishmaniasis for humans. Travelers to endemic areas must be taught that the only protective methods are those of protection against sandfly bites. These methods include limitation of outdoor activities, especially from sunset to sunrise when sandflies are frequently active; wearing protective clothing; and applying N, N-diethyl-meta-toluamide-containing repellents to uncovered skin. Because of weak flying ability of sandflies, use of fans or ventilators can inhibit their activity. In addition, sleeping in air-conditioned or well-screened areas and indoor spraying is advised. Since the highest activity of sandflies occurs when people are sleeping, the use of bed nets is one of the most important protection methods. The use of wide-mesh nets with a pyrethroid-containing insecticide can decrease sandfly biting rates. Also, there are some indoor...
Malaria

Malaria is caused by intraerythrocytic protozoa of different Plasmodium species. These parasites are transmitted to humans through the bite of female Anopheles mosquitoes. The most important cause of travel-related mortality and morbidity is malaria. In general, all travelers going to sub-Saharan Africa are at risk, unless their travel is entirely restricted to high altitudes, such as Mount Kilimanjaro. However, one study showed that the distribution of malaria is expected to shift with future climate changes with higher risks in African highlands, central Europe, and North America. Traveling to Oceania and West Africa is classified as high-risk travel for developing encephalitis due to malaria that requires chemoprophylaxis.

Ocular complications due to malaria disease are divided into two parts: the effects of the parasite on the eye and the ocular side effects of antimalarial drugs. Ocular involvement in malaria can occur in severe cases. Other studies have shown that retinopathy is associated with mortality in children with cerebral malaria. Malarial retinopathy contains of four distinct components: retinal whitening, retinal vessel wall discoloration to orange or white, hemorrhages, and papilledema [Figure 2].

The characteristic pattern of retinal whitening and vessel changes appears to be exclusive to malaria in a comatose patient, even if the peripheral blood smear is negative for malarial parasites. Amaurosis fugax, optic neuritis, glaucoma, panuveitis, oculomotor paralysis, and cortical blindness have been described in this disease.

In addition, eyes are affected by antimalarial drugs. Early retinopathy from chloroquine or hydroxychloroquine occurs in 10% and 2.7% of users, respectively. Bilateral pigment changes in the retinal pigment epithelium of the macula and bilateral enlarged blind spots have been seen in mefloquine users.

Treatment of systemic infection can cause improvements of ocular manifestations. Because severe or complicated cases of malaria can deteriorate suddenly during the early course of treatment, these patients should be admitted to hospital for at least 24 h. Treatment is also summarized in Table 1.

Prevention and recommendation: Malaria

Most travelers develop malarial disease because they were not aware of personal protection measures and/or chemoprophylactic regimens. All travelers to endemic areas for malaria should be educated about personal and environmental measures on protection against Anopheles mosquito bites. These measures include wearing clothing that covers as much skin as possible (long sleeves, long pants, and fully closed shoes with socks), using a repellent containing N,N-diethyl-3-meta-toluamide or picaridin, treating clothing with a pyrethroid in the regions with high risk for malaria, and sleeping under a permethrin-treated bed net in not well-screened or air-conditioned locations. Since the activity of the Anopheles mosquito is generally between dusk and dawn, limitation of outdoor night activity is advised. Chemoprophylaxis is necessary for any person traveling to high-transmission countries, especially in Africa. Multiple regimens for chemoprophylaxis exist and selection of them depends on patient preference, side-effect profile, cost, and drug susceptibility of Plasmodium species in the area. Also, there are some important diseases for travelers which are transmitted by mosquitoes. For example, dengue, filariasis, chikungunya, West Nile virus, yellow fever, dirofilariasis, Japanese encephalitis, tularemia, Saint Louis encephalitis, eastern equine encephalitis, western equine encephalitis, Venezuelan equine encephalitis, Ross River fever, La Crosse encephalitis, Zika fever, and Barmah Forest fever.

Acanthamoeba

Acanthamoeba species are ubiquitous protozoa that have been isolated from various natural environments such as sea water, fresh water lakes, soil, hot spring resorts, bottled water, and air.

Acanthamoeba keratitis (AK) is a severe infection of the cornea that can cause vision loss in some cases. Decreased vision in AK results from corneal ulceration and scarring. Keratitis frequently occurs in immunocompetent contact lens wearers. Contact lens hygiene is very important, but infection has been seen with some commercially available...
Corneal trauma has been considered to be a risk factor of AK in non-contact lens wearers. Other documented causes include swimming and showering with contact lenses in situ, exposure to contaminated water or soil, and corneal trauma. Some studies showed that AK was more prevalent during warmer seasons, especially during the summer,

This difference is perhaps due to more swimming and showering in summer.

The majority of symptoms reported in AK are nonspecific, including pain, eye redness, blurred vision, and photophobia. Early signs of AK include an epitheliopathy with punctate keratopathy and pseudodendrites [Figure 3a]. Ring infiltrate and perineuritis are specific signs in AK and present in only around 50% of patients [Figure 3b].

Clinical outcomes of AK are poor; the most severely infected eyes require keratoplasty or removal of the affected eye. Treatment of amebic keratitis is difficult and disappointing. Long-term topical application of agents such as propamidine, miconazole, and neomycin has been successful in only a few instances.

Treatment is also summarized in Table 1.

**Prevention and recommendation: Acanthamoeba**

Since diagnosis and treatment is difficult in AK, prevention is more effective. These include the following:

1. Wear, replace, and clean contact lenses and their cases according to the eye care provider and the manufacturer’s guidelines; 2. Remove contact lenses before carrying out any activity involving contact with water bodies such as swimming, showering, or using a hot tub; and 3. Avoid eye contamination or corneal trauma using adequate eye protection.

**American trypanosomiasis (Chagas’ disease)**

American trypanosomiasis, also known as kissing bugs and Chagas disease, is only seen on the American continent or among subjects who travel to rural areas of South and Central America. *Trypanosoma cruzi*, the causative parasite, is transmitted through the bite of reduviid bugs. The reservoir is in humans and domestic mammals, along with armadillos and opossums. Oral transmission through food or sugar cane juice contaminated by infected bugs may occur. Vertical transmission and infection through blood transfusion are important routes of infection and can take place in nonendemic areas.

Acute infection is rarely symptomatic. Some patients may complain of edema around the bite site or around the eye (Romanna’s sign), associated with fever and lymphadenopathy. In the chronic stage, the parasite will infiltrate to other organs, including cardiac conducting tissue, cardiac muscle, and smooth muscle of the gastrointestinal tract.

Two medications are available for treatment of American trypanosomiasis, including nifurtimox and benznidazole. Therapy is usually extended for a period of months, and parasitologic cure rates are somewhat disappointing. Both medications carry a long list of significant side effects. Supportive therapy, including surgery where necessary, is given as required for management of related complications. Treatment is also summarized in Table 1.

**Prevention and recommendation: American trypanosomiasis**

There are very little data regarding prevention of South American trypanosomiasis in travelers. The mainstay of control of the disease is vector control by indoor residual insecticide spraying and improvement of housing to prevent bugs becoming established in cracked walls and thatched roofing. Sugar cane presses and other food preparation facilities should be protected from possible contamination by infected reduviid bugs.

Travelers who are expecting to spend time in rural forested areas, particularly if living or sleeping in local accommodations, should be advised that this will increase their bite risk. It is advisable for travelers in such locations to sleep under a mosquito net and treat bedding with an insecticide to prevent bites.

**Toxoplasmosis**

*Toxoplasma gondii* is a protozoan parasite, the lifecycle of which passes through cats. It represents the commonest cause of uveitis worldwide. Human infection occurs through ingestion of food or water contaminated with cat feces. Toxoplasmosis may be acquired at any age but most commonly during childhood.

Humans become infected by this parasite when eating undercooked infected meat and by contamination with cysts following handling of cat litter trays.

Some patients may present with a glandular fever-like systemic febrile illness with adenopathy. Most cases of adult infection will not present with eye signs, but those that do usually present with a focal necrotizing retinitis occasionally associated with vascular occlusion.

The immunocompromized patients and neonates who have been exposed transplacentally by a mother’s acute infection are at particularly high risk for ocular complications.
Acute infection in newborns and patients infected with HIV may lead to an intense necrotizing chorioretinitis. More commonly, however, chorioretinitis is the result of necrotizing inflammation following the rupture of an older, slowly growing cyst, thus releasing bradyzoites. Ocular symptoms in the patient with congenital ocular toxoplasmosis may include strabismus, nystagmus, and blindness. Acute, acquired toxoplasmosis is associated with scotoma, photophobia, and loss of central vision due to macular involvement. Oculomotor nerve involvement may result in ptosis.

First-line therapy of chorioretinitis in toxoplasmosis includes the use of pyrimethamine with sulfadiazine and folinic acid to prevent bone marrow toxicity.

In addition, clindamycin and azithromycin are commonly used as first-line treatments. Therapy should continue for 1–2 weeks beyond the resolution of symptoms. Treatment is also summarized in Table 1.

Prevention and recommendation: Toxoplasmosis

Since serious consequences may arise if a pregnant woman is infected for the first time during travel, pregnant women should not eat undercooked meat to avoid vertical transmission. In France, steak tartare should be avoided. Barbecued meats should be well grilled or avoided.

Conclusions

Many travel-related eye diseases are preventable by education of health behaviors, using precautionary measures and taking chemoprophylactic medications or appropriate vaccinations for some diseases. The physicians in both endemic and nonendemic areas should become familiar with their clinical presentation and treatment strategies for earlier diagnosis of ocular lesions caused by parasitic infections to reduce costly, inappropriate laboratory evaluations, delayed or ineffective treatments, and severe complications including severe vision loss.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Received: 06 Apr 18 Accepted: 26 Jul 18 Published: 17 Sep 18

References

1. Korzeniewski K. Travel health prevention. Int Marit Health 2017;68:238-44.
2. Freedman DO, Chen LH, Kozarsky PE. Medical considerations before international travel. N Engl J Med 2016;375:247-60.
3. Pavli A, Maltezou HC. Leishmaniasis, an emerging infection in travelers. Int J Infect Dis 2010;14:e1032-9.
4. Gushulak BD, MacPherson DW. Globalization of infectious diseases: The impact of migration. Clin Infect Dis 2004;38:1742-8.
5. Velayati A, Sabari A. Travel medicine as an important aspect of global health; much still need to be done. Int J Travel Med Global Health 2014;1:1-2.
6. Isfelevajani MS. Travel risks and preventive strategies: An overview. Int J Travel Med Glob Health 2016;4:39.
7. Nimir AR, Salim A, Ibrahim IA. Ophthalmic parasitosis: A review article. Interdiscip Perspect Infect Dis 2012;2012:587402.
8. Cama VA, Mathison BA. Infections by intestinal coccidia and giardia duodenalis. Clin Lab Med 2015;35:423-44.
9. Swaminathan A, Torresi J, Schlagenhau P, Thursky K, Wilder-Smith A, Connor BA, et al. A global study of pathogens and host risk factors associated with infectious gastrointestinal disease in returned international travellers. J Infect 2009;59:19-27.
10. Shah N, Dufont HL, Ramsey DJ. Global etiology of travelers’ diarrhea: Systematic review from 1973 to the present. Am J Trop Med Hyg 2009;80:609-14.
11. Ekdahl K, Andersson Y. Imported giardiasis: Impact of international travel, immigration, and adoption. Am J Trop Med Hyg 2005;72:825-30.
12. Takaoka K, Gourtsyannis Y, Hart JD, Armstrong M, Daniel A, Mewse E, et al. Incidence rate and risk factors for giardiasis and strongylodiasis in returning UK travellers. J Travel Med 2016;23:1-6.
13. Izadi M, Sadepur A. A closer look to the most frequent travelers’ disease: A systematic update on travelers’ Diarrhea. Int J Travel Med Global Health 2014;2:95-9.
14. Halliez MC, Buret AG. Extra-intestinal and long term consequences of giardia duodenalis infections. World J Gastroenterol 2013;19:8974-85.
15. Petroello Mantovani M, Giardino I, Magli A, di Martino L, Guandalini S. Intestinal giardiasis associated with ophthalmologic changes. J Pediatr Gastroenterol Nutr 1990;11:196-200.
16. Khalifa E, El‑Nothby K, Ali A, El‑Maslah A, Negm O. Ocular changes in giardiasis: Human and experimental studies. Tanta Med Sci J 2007;2:119-31.
17. Tumbull AM, Lin Z, Matthews BN. Severe bilateral anterior uveitis secondary to giardiasis, initially misdiagnosed as a side effect of metronidazole. Eye (Lond) 2013;27:1225-6.
18. Corsi A, Nucci C, Knafelz D, Bulgarin D, Di Iorio L, Polito A, et al. Ocular changes associated with Giardia lamblia infection in children. Br J Ophthalmol 1998;82:59-62.
19. El‑Sayed NM, Safar EH. Characterization of the parasite-induced lesions in the posterior segment of the eye. Indian J Ophthalmol 2015;63:881-7.
20. Ortiz JJ, Ayoub A, Gargala G, Chegne NL, Favennecc L. Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru. Aliment Pharmacol Ther 2001;15:1409-15.
21. Mørch K, Hanevik K, Robertson LJ, Strand EA, Langeland N. Treatment‑ladder and genetic characterisation of parasites in refractory giardiasis after an outbreak in Norway. J Infect 2008;56:268-73.
22. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005;366:1561-77.
23. Mansueto P, Seidita A, Vitale G, Cascio A. Leishmaniasis in travelers: A literature review. Travel Med Infect Dis 2014;12:563-81.
24. Alvar J, Veléz ID, Bern C, Herrero M, Desjeux P, Cano J, et al.
Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012;7:e35671.
25. Sharifi I, Aflatoonian MR, Fekri AR, Hakimi Parizi M, Aghaei Afshar A, Khosravi A, et al. A comprehensive review of cutaneous leishmaniasis in kerman province, Southeastern Iran-narrative review article. Iran J Public Health 2015;44:290-307.
26. Lübbert C, Optitz BM, Harms-Zwingerberger G, Nietzsch HH. Fever, pancytopenia, and splenomegaly 8 months after a trip to Majorca Island (Spain). Med Klin (München) 2008;103:29-35.
27. Berens-Riha N, Fleischmann E, Pratlong F, Bretzel G, von Sonnenburg F, Löschter T. Cutaneous leishmaniasis (Leishmania tropica) in a German tourist after travel to greece. J Travel Med 2009;16:220-2.
28. Schmid MB, Leichsenring M, Keller C, Hegasy G. Pancytopenia, fever, and splenomegaly in a 2-year-old boy. Disch Med Wochenschr 2009;134:1274-7.
29. Besada E, Njalla RJ, Nossent JC. Imported case of visceral leishmaniasis presenting as pancytopenia in a Norwegian patient treated with methotrexate and etanercept for psoriasis arthritis. Rheumatol Int 2013;33:2687-9.
30. Ehehalt U, Schunk M, Jensenius M, van Genderen PJ, Röder M, Mehler MR, Schaub J, et al. Leishmaniasis acquired by travellers to endemic regions in Europe: A EuroTravNet multi-centre study. Travel Med Infect Dis 2014;12:167-72.
31. Chaudhry IA, Hylton C, DesMarchais B. Bilateral ptosis and lower eyelid ectropion secondary to cutaneous leishmaniasis. Arch Ophthalmol 1998;116:1244-5.
32. Satici A, Gurler B, Gurel MS, Aslan G, Oguz H. Mechanical ptosis and lagophthalmos in cutaneous leishmaniasis. Br J Ophthalmol 1998;82:975.
33. Aykut FA, Wolde YA, Hagos T, Diro E. Ocular leishmaniasis presenting as chronic ulcerative blepharconjunctivitis: A case report. J Clin Exp Ophthalmol 2015;6:1-2.
34. Durdu M, Gökçe S, Bagirova M, Valaz M, Allahverdiyev AM, Unz U. Periorbital involvement in cutaneous leishmaniasis. J Eur Acad Dermatol Venereol 2007;21:214-8.
35. Maude RJ, Ahmed BU, Rahman AH, Rahman R, Majumder MI, Mendez DB, et al. Retinal changes in visceral leishmaniasis by retinal photography. BMC Infect Dis 2014;14:527.
36. Montero JA, Ruiz-Moreno JM, Sanchis E. Intraretinal hemorrhage associated with leishmaniasis. Ophthalmic Surg Lasers Imaging 2003;34:212-4.
37. Sundar S, Chakravarty J. An update on pharmacotherapy for leishmaniasis. Expert Opin Pharmacother 2015;16:237-52.
38. Kumar R, Engwerda C. Vaccines to prevent leishmaniasis. Expert Opin Pharmacother 2015;16:237-52.
39. Davies CR, Kaye P, Croft SL, Sundar S. Leishmaniasis: New approaches to disease control. BMJ 2003;326:377-82.
40. Kroeger A, Avila EV, Morison L. Insecticide impregnated curtains to control domestic transmission of cutaneous leishmaniasis in Venezuela: Cluster randomised trial. BMJ 2002;325:810-3.
41. Muller GC, Jumila A, Kravchenko VD, Revay EE, Butlers J, Schlein Y. Indoor protection against mosquito and sand fly bites: A comparison between citronella, linalool, and geraniol candles. J Am Mosq Control Assoc 2008;24:150-3.
42. Hahn WO, Pottinger PS. Malaria in the traveler: How to manage before departure and evaluate upon return. Med Clin North Am 2016;100:289-302.
43. World Health Organization. Malaria Rapid Diagnostic Test Performance: Results of WHO Product Testing of Malaria RDTs: Round 6 (2014-2015). Geneva: World Health Organization, 2015.
44. Leder K, Torresi J, Libman MD, Cranler JP, Castelli F, Schlagenhauf P, et al. GeoSentinel surveillance of illness in returned travelers, 2007-2011. Ann Intern Med 2013;158:456-68.
45. Elliott JH, O’Brien D, Leder K, Kitchener S, Schwartz E, Weld L, et al. Imported plasmodium vivax malaria: Demographic and clinical features in nonimmune travelers. J Travel Med 2004;11:213-7.
46. Km Engineers C, Kovats S, Rocklov J, Tompkins AM, Morse AP, Colón-González FJ, et al. Impact of climate change on global malaria distribution. Proc Natl Acad Sci U S A 2014;111:3326-91.
47. Elliott JH, O’Brien D, Leder K, Kitchener S, Schwartz E, Weld L, et al. Imported plasmodium vivax malaria: Demographic and clinical features in nonimmune travelers. J Travel Med 2004;11:213-7.
48. Barrera V, Hiscott PS, Craig AG, White VA, Milner DA, Beare NA, et al. Severity of retinopathy parallels the degree of parasite sequestration in the eyes and brains of Malawian children with fatal cerebral malaria. J Infect Dis 2015;211:1977-86.
49. Singh J, Verma R, Tiwari A, Mishra D, Singh HP. Retinopathy as a prognostic marker in cerebral malaria. Indian Pediatr 2016;53:315-7.
50. Beare NA, Taylor TE, Harding SP, Lewallen S, Molyneux ME. Malarial retinopathy: A newly established diagnostic sign in severe malaria. Am J Trop Med Hyg 2006;75:790-7.
51. Beare NA, Lewallen S, Taylor TE, Molyneux ME. Redefining cerebral malaria by including malarial retinopathy. Future Microbiol 2011;6:349-55.
52. AlKadi HO. Antimalarial drug toxicity: A review. Chemotherapy 2007;53:385-91.
53. Walker RA, Colleaux KM. Maculopathy associated with meltoquine (Lariam) therapy for malaria prophylaxis. Can J Ophthalmol 2007;42:125-6.
54. Melo Mde M, Ciriano JP, van Genderen PJ. Narrow vision after travel to greece. J Travel Med 2009;16:220-2.
55. Lalloo DG, Shingadha D, Bell DJ, Beeching NJ, Whitty CJ, Chandini PL, et al. UK malaria treatment guidelines 2016. J Infect 2016;72:635-49.
56. Ladhani S, Albaura RJ, Riordan FA, Shingadha D. Imported malaria in children: A review of clinical studies. Lancet Infect Dis 2007;7:349-57.
57. Freedman DO. Clinical practice. Malaria prevention in short-term travelers. N Engl J Med 2008;359:603-12.
58. Mirzaai E, Durham MJ, Hess K, Goad JA. Mosquito-borne illnesses in travelers: A review of risk and prevention. Pharmacotherapy 2010;30:1031-43.
59. Marciano-Cabral F, Cabral G. Acanthamoeba spp. As agents of disease in humans. Clin Microbiol Rev 2003;16:273-307.
60. Zanetti S, Fiori PL, Pinna A, Fadda G. Susceptibility of Acanthamoeba castellanii to contact lens disinfecting solutions. Br J Ophthalmol 1998;82:975.
61. Siddiqui R, Khan NA. Biology and pathogenesis of Acanthamoeba. Parasit Vectors 2012;5:6.
62. Siddiqui R, Khan NA. Biology and pathogenesis of Acanthamoeba. Parasit Vectors 2012;5:6.
63. Joslin CE, Tu EY, McMahon TT, Passaro DJ, Stayner LT, Tai AT, et al. Surveillance of adverse events associated with miconazole nasal solution: A comparison between citronella, linalool, and geraniol candles. J Travel Med 2013;20:197-203.
64. Zanetti S, Fiori PL, Pinna A, Fadda G. Susceptibility of Acanthamoeba castellanii to contact lens disinfecting solutions. Br J Ophthalmol 1998;82:975.
65. Rahimi F, Rafizadeh SM, Beheshtnejad AH, Hashemian MN, Zare MA, Siatiri H, et al. Acanthamoeba keratitis and its associated risk factors in Farabi eye hospital of Tehran. Iranian Journal of Ophthalmology 2013; 25:297-303.

66. Yamazoe K, Yamamoto Y, Shimazaki-Den S, Shimazaki J. Visual outcome in Japanese patients with acanthamoeba keratitis. Eye (Lond) 2012;26:517-22.

67. Jiang C, Sun X, Wang Z, Zhang Y. Acanthamoeba keratitis: Clinical characteristics and management. Ocul Surf 2015;13:164-8.

68. Bacon AS, Dart JK, Ficker LA, Matheson MM, Wright P. Acanthamoeba keratitis. The value of early diagnosis. Ophthalmology 1993;100:1238-43.

69. Ross J, Roy SL, Mathers WD, Ritterband DC, Yoder JS, Ayers T, et al. Clinical characteristics of Acanthamoeba keratitis infections in 28 states, 2008 to 2011. Cornea 2014;33:161-8.

70. Maycock NJ, Jayaswal R. Update on acanthamoeba keratitis: Diagnosis, treatment, and outcomes. Cornea 2016;35:713-20.

71. Tanhehco T, Colby K. The clinical experience of Acanthamoeba keratitis at a tertiary care eye hospital. Cornea 2010;29:1005-10.

72. Lorenzo-Morales J, Martín-Navarro CM, López-Arencibia A, Arnalich-Montiel F, Piñero JE, Valladares B. Acanthamoeba keratitis: An emerging disease gathering importance worldwide? Trends Parasitol 2013;29:181-7.

73. Moncayo A, Silveira AC. Current epidemiological trends for chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem Inst Oswaldo Cruz 2009;104 Suppl 1:17-30.

74. Moncayo A, Ortiz Yanine MI. An update on chagas disease (human American trypanosomiasis). Ann Trop Med Parasitol 2006;100:663-77.

75. Diazgranados CA, Saavedra-Trujillo CH, Mantilla M, Valderrama SL, Alquichire C, Franco-Paredes C. Chagasic encephalitis in HIV patients: Common presentation of an evolving epidemiological and clinical association. Lancet Infect Dis 2009;9:324-30.

76. McCannel CA, Holland GN, Helm CJ, Cornell PJ, Winston JV, Rimmer TG. Causes of uveitis in the general practice of ophthalmology. UCLA community-based uveitis study group. Am J Ophthalmol 1996;121:35-46.

77. Rathinam SR, Cunningham ET Jr. Infectious causes of uveitis in the developing world. Int Ophthalmol Clin 2000;40:137-52.

78. Engstrom RE Jr., Holland GN, Nussenblatt RB, Jabs DA. Current practices in the management of ocular toxoplasmosis. Am J Ophthalmol 1991;111:601-10.